Eli Lilly lifts sales outlook as Zepbound surges
CNBC · RSS · · AI-summarised by FinFlash
Eli Lilly raised its sales outlook after third-quarter results showed another surge in its obesity drug Zepbound and diabetes treatment Mounjaro. The company's chief executive said there is room for "dramatic" expansion of the obesity market. Lilly is the largest U.S. healthcare company by market value.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.